TruSight Oncology 500 Portfolio

Enable Comprehensive Genomic Profiling

Assess all key biomarkers in guidelines, as well as clinical trials, increasing the chances of finding a positive biomarker for every sample. Including all key genomic variants, plus the immuno-oncology biomarkers MSI and TMB (emerging), our assays enable a lab to consolidate several independent assays and workflows into a single one, at the same time saving sample, time, and money.

Bring the Assay into Your Lab

Implement the assay in your own lab, to better serve your local community, maintain control of sample and data, and become an active part of the molecular tumor board. With content including current and emerging biomarkers, plus an IVD roadmap in partnership with several pharmaceutical companies, these assays are made to stay in a lab for the long run.

Integrated, Flexible, and Scalable Workflow

Analyze all key biomarkers in a single, verified workflow using the DRAGEN Bio-IT Platform for secondary analysis (now available on-premise or via the cloud with ICA, Illumina Connected Analytics) and Pierian Clinical Genomics Workspace (CGW) for a final interpretation report. Benefit from the portfolio's flexibility with assays for either solid or liquid biopsy samples, automation-friendly options, and scalable batch sizes.

Achieve Timely and Reliable Results

Achieve timely results within 4-5 days with a reliable family of assays offering 99.999% analytical specificity and >95% analytical sensitivity due to robust hybrid-capture chemistry, SBS sequencing, and sophisticated bioinformatics.